Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (May 2024)
28 slides from Beta Drugs's investor presentation, May 14, 2024
Slide 1: Investor Presentation 2023-2024
“N BETA DRUGS LTD. Dedicated to Oncology... INVESTOR PRESENTATION 2023-2024
Slide 2: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 3: We Are…
We Are… A global pharma company. Our mission is to develop and deliver high-quality, affordable oncology medicines that improve patients' lives. The most trusted manufacturer in cytotoxic segment since 15 years Manufacturer of widest One of the fastest growing range of branded Oncology company in In
Slide 4: Key Business Highlights FY'24
Key Business Highlights FY’24 Forbes Asia Separate plant Caxfila OS- 30% revenue EAEU “Best under a for syrups/ 1st Indian brand of growth approval Billion Award” suspensions Megestrol Acetate Suspension PAN India Collaboration 53 new Filed six presence: with an European registrations in syrups/susp
Slide 5: The Journey So Far…
The Journey So Far… Top Line growth Gross profit growth Value in Crs Value in Crs 146.3 296 121.4 CAGR: 34% 227 CAGR: 33% 89.4 184 57.3 116 46.5 91 FY 19-20 FY 20-21 FY 21-22 FY 22-23 FY 23-24 FY 19-20 FY 20-21 FY 21-22 FY 22-23 FY 23-24 Superior Profitability (EBITDA) Net profit growth Value in Crs
Slide 6: Manufacturing Key Differentiator
Key Differentiator Formulation and API plant High level of vertical integration from 3 Manufacturing facilities conception to commercialization 70% of API requirements are manufactured in-house 120+ SKUs Manufacturing wide range of finished formulation products Strong R&D Various forms of oral solid
Slide 7: Customer-Centric Approach
Customer-Centric Approach Superior business outcome Highly satisfied customers Enduring relationship
Slide 8: Business Overview
<N BETA < DRUGS LTD. Business Overview
Slide 9: Sustainable Growth
Sustainable Growth Overall business growth Revenue split across different verticals 58% 28% 30% 24% FY 20-21 FY 21-22 FY 22-23 FY 23-24 Growth in FY ‘24 Domestic Own CDMO Business 23% Brand Business 28% 3 Yrs CAGR: 20% 3 Yrs CAGR: 27% International API 65% Business 15% Business 3 Yrs CAGR: 47% 3 Yrs
Slide 10: Domestic Own Brand: Oncology
Domestic Own Brand: Oncology CAGR: 27% Launch of Caxfila OS : 1st Indian brand of Megestrol Acetate suspension Launch of Canrib: 1st Indian’s most affordable brand of Olaparib Seven new brands launched Build sales of Oral formulations for more sustainable growth Strengthened the Hemato portfolio
Slide 11: Domestic Own Brand: Oncology
Domestic Own Brand: Oncology Leading Brands in Oncology
Slide 12: Domestic Own Brand: Oncology
Domestic Own Brand: Oncology Future target markets for volume & sustainable growth Cytotoxic Hormonal Supportive Nibs/Mabs 70% market 55% market 26% market 40% market coverage coverage coverage coverage
Slide 13: Domestic Own Brand: Cosmeceutical
Domestic Own Brand : Cosmeceutical - PAN India presence Touched the 1st - Increased reach to 6000 customers milestone of 1 Cr sales/month (Apr’24) Presence A big leap… Grow Acquire Expand Increased prescriber base from 700 to 1100 • Expanded portfolio • Agreement with the European company for the Fi
Slide 14: International Business
International Business Present in more than 46 countries 250+ registrations
Slide 15: International Business
International Business Growth drivers Geo expansion in 18 new 53 new registrations countries in FY’24 Colombia, Mexico, Azerbaijan, South South East Asia: 8 Africa, Malaysia, Vietnam, Thailand, LATAM: 28 Philippines, Zimbabwe, Morocco, Algeria, Curacao, St Martin, Aruba, Middle East & Africa: 17 Zam
Slide 16: API Business
API Business CERITINIB REGORAFENIB PALBOCICLIB
Slide 17: API Business
API Business 70% API facility with a world- Wide portfolio of API of API for formulations class microbial lab with the related to Oncology drugs manufactured in-house latest equipment API business provides competitive advantage Sales Growth CAGR: 38% Strategic business enabler for the manufacturing
Slide 18: CDMO Business
CDMO Business ✓ Partnership with 50+ companies ✓ 20+ top pharma companies are associated with us since last 5 years ✓ Capacity of lyophilized products has increased. It helped to reduce lead time for order execution Sales growth CAGR: 20% FY 21-22 FY 22-23 FY 23-24
Slide 19: Future Roadmap
Future Roadmap
Slide 20: Future Roadmap
Future Roadmap 450+ Cr. 296 Cr. 227 Cr. FY’26 FY’24 FY’23 FY’22 FY’21 The company plans to establish its presence and expand in Indian & international markets
Slide 21: Innovation: Focus on R&D
Innovation: Focus on R&D Strong product pipeline
Slide 22: Focus on Performance
Focus on Performance Domestic Branded Market Oncology Cosmeceutical • To achieve leadership position in the • Focus on productivity enhancement cytotoxic market • Continuously innovate to ensure high • Focus on building 10 Cr & above brands brand equity with doctors • Further strengthening Hemato &
Slide 23: Focus on Performance
Focus on Performance International Market Robust pipeline ahead Existing registrations Pipeline Middle East & LATAM 60 Africa LATAM 46 South East South East Asia Middle East & Africa 109 86 150 Asia 80 CIS: 60 CIS: 15 256 registrations as on date 350+ registrations in pipeline
Slide 24: Focus on Performance
Focus on Performance API CDMO • Continuously enhance systems, processes, • Focus on productivity enhancement and human capabilities to ensure compliance with global regulatory • Focus on profitable growth standards • Reduce lead time for order executions • Foraying into the European market • New cus
Slide 25: Financial Overview
Financial Overview
Slide 26: Financial Ratios
Financial Ratios --------------------------------------- Current ratio EPS 37.90 2.10 31.95 25.82 2.03 1.98 FY'22 FY'23 FY'24 FY'22 FY'23 FY'24 ----------------------------------------------------------------------------------------------------------------------------------- Debt to equity ratio 0.2
Slide 27: Balance Sheet
Balance Sheet FY’22 FY’23 FY’24 (Rs Cr) (Rs Cr) (Rs Cr) Share Capital 9.61 9.61 9.61 Reserves 82.73 113.27 147.5 Borrowing (Long term & 16.58 16.04 11 Short term) Other liabilities 48.93 59.5 85.99 Total Liabilities 157.85 198.42 254.1 Fixed asset 54.96 62.76 64.59 CWIP 0 0 0 Investment 0.78 0.78 0
Slide 28: Thank You
THANK YOU Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India) Website: www.betadrugslimited.com Email: info@betadrugslimited.com